Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?

Bibliographic Details
Title: Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
Authors: Massimiliano Mirabella, Pietro Annovazzi, Wallace Brownlee, Jeffrey A. Cohen, Christoph Kleinschnitz, Christian Wolf
Source: Frontiers in Neurology, Vol 13 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Neurology. Diseases of the nervous system
Subject Terms: disease modifying treatment, glatiramer acetate, special populations, multiple sclerosis, comorbidities, Neurology. Diseases of the nervous system, RC346-429
More Details: Earlier diagnosis, access to disease-modifying therapies (DMTs), and improved supportive care have favorably altered the disease course of multiple sclerosis (MS), leading to an improvement in long-term outcomes for people with MS (PwMS). This success has changed the medical characteristics of the population seen in MS clinics. Comorbidities and the accompanying polypharmacy, immune senescence, and the growing number of approved DMTs make selecting the optimal agent for an individual patient more challenging. Glatiramer acetate (GA), a moderately effective DMT, interacts only minimally with comorbidities, other medications, or immune senescence. We describe here several populations in which GA may represent a useful treatment option to overcome challenges due to advanced age or comorbidities (e.g., hepatic or renal disease, cancer). Further, we weigh GA's potential merits in other settings where PwMS and their neurologists must base treatment decisions on factors other than selecting the most effective DMT, e.g., family planning, conception and pregnancy, or the need for vaccination.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1664-2295
Relation: https://www.frontiersin.org/articles/10.3389/fneur.2022.844873/full; https://doaj.org/toc/1664-2295
DOI: 10.3389/fneur.2022.844873
Access URL: https://doaj.org/article/83b83205b59a479d971ed9234235e952
Accession Number: edsdoj.83b83205b59a479d971ed9234235e952
Database: Directory of Open Access Journals
More Details
ISSN:16642295
DOI:10.3389/fneur.2022.844873
Published in:Frontiers in Neurology
Language:English